Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 9/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.36 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4038694 | 0.93 | CTSK (0.39) | CTSKPOLBHPGDCHRNB2CHRNA7 | |
| SCHEMBL4042580 | 0.92 | CTSK (0.49) | CTSKCTSSCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4043304 | 0.91 | CTSK (0.49) | CTSKCTSSCHRNB2CHRNA7CHRNA4 | |
| SCHEMBL4043635 | 0.91 | CTSK (0.52) | CTSKCTSSACEGPR132 | |
| SCHEMBL4041490 | 0.90 | CTSK (0.51) | CTSKCTSSACESMYD3 | |
| SCHEMBL3958840 | 0.90 | CTSK (0.53) | CTSKCTSSACESMYD3GPR132 | |
| SCHEMBL4042964 | 0.90 | CTSK (0.49) | CTSKPOLBCTSS | |
| SCHEMBL4037649 | 0.89 | CTSK (0.51) | CTSKPOLBCTSSACESMYD3 | |
| SCHEMBL4040613 | 0.89 | CTSK (0.61) | CTSKHPGDCTSSACESMYD3 | |
| SCHEMBL4043775 | 0.88 | CTSK (0.50) | CTSKPOLBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1692135-A4 | A NEW PROCESS FOR PREPARATION OF IMIPENEM | CHOONGWAE PHARMA CORP (KR) | 2009-02-25 | — | — | EP | disclosed |
| EP-1463728-B1 | FUSED CYCLIC MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION | BRISTOL MYERS SQUIBB CO (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-1692135-A1 | A NEW PROCESS FOR PREPARATION OF IMIPENEM | Choongwae Pharma Corporation (KR) | 2006-08-23 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| WO-2005056553-A1 | A NEW PROCESS FOR PREPARATION OF IMIPENEM | CHOONGWAE PHARM.CO. (KR) | 2005-06-23 | — | — | WO | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885POLB 3780/4885HPGD 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.